Verano Holdings Corp banner
V

Verano Holdings Corp
CNSX:VRNO

Watchlist Manager
Verano Holdings Corp
CNSX:VRNO
Watchlist
Price: 5.01 CAD -10.22% Market Closed
Market Cap: CA$1.8B

P/OCF

13.7
Current
1%
More Expensive
vs 3-y average of 13.6

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
13.7
=
Market Cap
CA$1.7B
/
Operating Cash Flow
$91.4m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
13.7
=
Market Cap
CA$1.7B
/
Operating Cash Flow
$91.4m

Valuation Scenarios

Verano Holdings Corp is trading above its 3-year average

If P/OCF returns to its 3-Year Average (13.6), the stock would be worth CA$4.95 (1% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-3%
Maximum Upside
No Upside Scenarios
Average Downside
1%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 13.7 CA$5.01
0%
3-Year Average 13.6 CA$4.95
-1%
5-Year Average 13.7 CA$5
0%
Industry Average 13.5 CA$4.93
-2%
Country Average 13.3 CA$4.87
-3%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
US
Verano Holdings Corp
CNSX:VRNO
1.7B CAD 13.7 -4.5
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 49.7 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 22.3 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 13.7 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 19.7 28.2
CH
Novartis AG
SIX:NOVN
218.2B CHF 14.3 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 16.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 907.7 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 9.7 11.3
US
Pfizer Inc
NYSE:PFE
153.5B USD 13.1 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 8.3 16.8
P/E Multiple
Earnings Growth PEG
US
V
Verano Holdings Corp
CNSX:VRNO
Average P/E: 21.9
Negative Multiple: -4.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28.2
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

In line with most companies in the United States of America
Percentile
52st
Based on 9 488 companies
52st percentile
13.7
Low
0 — 8.8
Typical Range
8.8 — 20.1
High
20.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 8.8
Median 13.3
70th Percentile 20.1
Max 3 188 432.5

Verano Holdings Corp
Glance View

Market Cap
1.8B CAD
Industry
Pharmaceuticals

In the burgeoning landscape of the cannabis industry, Verano Holdings Corp. emerges as a key player, crafting a narrative of growth and innovation. Founded with an ambition to bring premium cannabis products to the forefront of the market, Verano operates across a diverse array of segments, tapping into both the medicinal and recreational sectors. The company stands out due to its vertically integrated model, which means it controls the entire supply chain, from cultivation and production to distribution and retail. This model not only ensures quality and consistency but also allows Verano to capture value at every step of the process. Through meticulous cultivation practices and state-of-the-art facilities, Verano develops a wide range of products, including flower, edibles, and concentrates, which are distributed under its house of premium brands in various markets across North America. Verano's financial engine is powered by its extensive network of retail outlets—known as Zen Leaf and MÜV dispensaries—and its aggressive expansion strategy into emerging markets. This retail footprint is crucial, providing direct access to consumers and fostering a loyal customer base. Verano continuously enhances its product offerings by focusing on innovation and responding adeptly to consumer trends, thereby driving sales and margin growth. Its adept navigation of complex regulatory environments reflects a keen understanding of market dynamics, allowing it to take advantage of growth opportunities in a sector that remains highly regulated. By marrying operational efficiency with a deep commitment to delivering high-quality, consistent cannabis products, Verano not only sustains profitability but also positions itself strategically for future growth in an evolving industry landscape.

VRNO Intrinsic Value
Not Available
V
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett